Fyarro(sirolimus) albumin has shown significant effectiveness in the treatment of malignant perivascular epithelioid cell tumors, not only improving the survival rate of patients, but also having long-term efficacy, providing new possibilities for the treatment of this rare sarcoma.
How to use Fyarro(sirolimus) albumin
Fyarro(sirolimus) albumin is a white to yellow sterile lyophilized powder, which needs to be reconstituted before use and administered intravenously.
1. Drug characteristics and administration method
Before using the drug, an appropriate amount of lyophilized powder needs to be dissolved in an appropriate solvent to form an injectable solution. This reconstitution process needs to be carried out in accordance with the instructions of the drug instructions to ensure the stability and effectiveness of the drug. The administration of Fyarro(sirolimus) albumin is by intravenous injection. During the treatment process, the doctor will determine the recommended dose for each cycle based on the patient's specific situation and the required dose. Generally speaking, the recommended dose is 100mg/m2, which means that the dose will be adjusted according to the patient's body surface area to achieve individualized treatment.
2. Treatment cycle and administration frequency
The treatment cycle of Fyarro(sirolimus) albumin is 21 days. On the first and eighth days of each cycle, patients need to receive the drug by intravenous infusion. The duration of the infusion is usually 30 minutes, and the doctor will adjust the infusion rate according to the patient's specific situation and the tolerance of the drug.
Treatment will continue until the disease progresses or the patient has unacceptable toxicity. During treatment, the doctor will closely monitor the patient's condition and the efficacy of the drug, and deal with possible adverse reactions in a timely manner.
Common adverse reactions of Fyarro(sirolimus) albumin
Fyarro(sirolimus) albumin may also cause the following adverse reactions while treating adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumors. The following are common ones:
1. Weight loss
During the treatment with Fyarro(sirolimus) albumin, some patients may experience weight loss. This is because Fyarro(sirolimus) albumin has a certain effect on the patient's appetite. It is recommended that patients pay attention to a balanced diet during treatment, increase nutritional intake, and work with their doctors to develop a reasonable diet plan to maintain good health.
2. Loss of appetite
In addition to weight loss, some patients may also experience a loss of appetite during the use of Fyarro(sirolimus) albumin. This may lead to insufficient calories and nutrition intake by patients, which in turn affects the patient's physical condition and quality of life. It is recommended that patients communicate with their doctors in a timely manner, seek guidance from nutritionists or other professionals, and develop a scientific and reasonable diet plan to meet the body's nutritional needs.
3. Cough
Cough is a common adverse reaction of Fyarro(sirolimus) albumin, which may be due to the drug's irritation to the respiratory system, causing the patient to have symptoms of coughing.
In addition to the above common adverse reactions, Fyarro(sirolimus) albumin may also cause other adverse reactions, such as stomatitis, fatigue, rash, etc. The incidence and severity of these adverse reactions vary from patient to patient. Patients should pay close attention to their own physical reactions during the use of the drug and report to the doctor in a timely manner so that the doctor can adjust the treatment plan according to the specific situation and provide personalized support and guidance.
As a patient, you should maintain close communication with your doctor during the use of Fyarro(sirolimus) albumin and treat it according to the doctor's instructions. At the same time, pay attention to the body's reaction and inform the doctor of adverse reactions in a timely manner so that the doctor can intervene and adjust the treatment plan in time to ensure the safety and efficacy of drug treatment.
